This book serves as a tribute to the work of the many investigators who have attempted to understand the role of the androgen receptor (AR) in the development and progression of prostate cancer. The relationship between prostate cancer and androgen status was initially appreciated in the late 1800s, and then awareness reawakened in the 1940s (Huggins and Hodges 2002) by the studies of Charles Huggins and colleagues, for which the Nobel prize was awarded in 1966. Androgen deprivation therapy by surgical or medical means using methods that remove the source of testicular androgens or inhibit the production of testicular androgens, respectively, produced remission in most, but not all, men. Moreover, clinical studies have cast doubt on whether ''combined androgen blockade'' (Labrie et al. 1982 ) is any more effective than androgen deprivation monotherapy (Prostate Cancer Trialists' Collaborative Group, 1995) , except when an antiandrogen is used to block testosterone flair in men with bulky metastatic disease. Nonetheless, responses to androgen deprivation therapy vary widely. In order to explain this clinical variation, it was proposed initially that prostate cancer consists of ''androgen-dependent'' and ''androgen-independent'' cells (Carter and Isaacs 1988; Isaacs and Coffey 1981) . The argument went as follows:
The relative distribution of prostate cancer cells between these two phenotypes determine whether there is a clinical response to androgen deprivation therapy and the duration of any response. If the tumor consists of androgen-dependent cells entirely, androgen deprivation therapy would prove curative since all androgen-dependent cells would undergo apoptosis upon androgen deprivation. If a prostate cancer is composed exclusively of androgenindependent cells, then no clinical response to androgen deprivation therapy would occur and that patient would ''resist'' androgen deprivation therapy and succumb to his prostate cancer as if androgen deprivation therapy had never been administered. Almost, if not, all patients fall between these two extremes and exhibit clinical remissions, which may be complete and sustained if the androgen-dependent cells far outnumber the androgenindependent cells. Because apoptosis does not occur in as high a proportion of cells as predicted, a third phenotype of prostate cancer cell was proposed, the androgen-sensitive cell (Pollack et al. 1983; Grossman 1986 ). The ''androgen-sensitive'' cell is responsive to androgen deprivation therapy by becoming quiescent until such time that androgens become available. Thus, the extent of regression of prostate cancer after androgen D. Tindall and J. Mohler (eds.), Androgen Action in Prostate Cancer, 1 DOI: 10.1007/978-0-387-69179-4, # Springer Science + Business Media, LLC 2009 deprivation therapy is influenced by the relative proportion of androgen-dependent, androgen-sensitive and androgen-independent cells. The eventual emergence of the ''androgen-independent phenotype'' is predicted by the proportion of androgen-independent cells.
The development of prostate cancer cell lines, prostate cancer cell line xenografts, and human prostate cancer xenografts has enabled translational researchers to model manifestations of clinical disease progression. The availability of these models has resulted in increased complexity in terminology. Many commercially available tissue culture media contain levels of androgens sufficient to activate even a normal androgen receptor. However, a truly androgen-independent state can be achieved in a cell culture environment by careful charcoal stripping of media and the avoidance of inclusion of phenol red. Hence, investigators should prove that their androgen-free media is truly androgen free lest results be compromised. In the in vitro situation, proper terminology allows for androgen-dependent, androgensensitive, or androgen-independent growth. An androgen-dependent cell line is one that is comprised exclusively of androgen-dependent cells, which undergo apoptosis upon androgen withdrawal. Restoration of androgen after a certain period would have no effect since all cells would have died. Even the LNCaP cell line does not meet this definition. LNCaP cells vary their growth rate many fold depending on androgen levels and exhibit a well-known bimodal growth response to androgens; androgen levels either too low or too high inhibit growth (Gregory et al. 2001 ). Thus, LNCaP should be considered an androgen-sensitive cell line in which the vast majority undergoes apoptosis but some cells become quiescent, i.e., growth ceases until such time that androgens are restored in the media. LNCaP cells grown in progressively androgen-depleted media selects for ''androgen-independent'' variants. But androgen response may be even more complicated; although xenografted cells grow equally well in castrate or intact hosts, they decrease growth rate approximately twofold upon androgen stimulation (Lee et al. 2007 ). Other ''androgen-independent'' cells, such as CWR-R1 and LNCaP-C4-2, increase growth twofold when androgens are added to the media (Gregory et al. 2001) .
Even greater difficulties ensue when the terms androgen-dependent, androgensensitive, and androgen-independent are applied to xenografts and patients. The mouse has widely fluctuating levels of testosterone, and most investigators control testosterone levels by surgical castration and implantation of sustained-release pellets to provide physiologically relevant (human) androgen stimulation of xenografted cell lines or clinical specimens. However, the laboratory mouse differs markedly from the human. Testicular androgen levels in the castrate mouse are below the level of detection using radioimmunoassay and routine mass spectrometric measurement (Van Steenbrugge 1991; Jin et al. 2004 ). However, clinically significant circulating DHEA levels may be similar in intact and castrate BALB/c nude mice (Jin et al. 2004 ). Removal of sustained release androgen pellets creates an androgen deprivation therapy situation different than in the human due to the availability in the human of very high levels of circulating low-affinity andrenal androgens. In addition, many androgen-sensitive cell lines (LNCaP, LAPC4), androgen-dependent xenografts (CWR22, LUCaP), or clinical specimens (fresh tissue samples) require orthotopic seeding, which is challenging technically, or coadministration with Matrigel 1 for establishment and growth, even in the face of normal circulating levels of testicular androgens.
In the human patient, advanced prostate cancer is treated with androgen deprivation therapy. In rare cases, no clinically measureable response will occur, and the tumor should be labeled appropriately ''castration-resistant prostate cancer'' (Scher and Sawyers 2005) . However, most men experience a clinical and/or biochemical regression and, hence, their tumor should be considered either androgen-dependent or -sensitive. Unfortunately, an androgen-dependent tumor cannot be distinguished from an androgen-sensitive tumor in a human because of the inability to assess accurately the degree of apoptosis vs. cell quiescence, since biopsy specimens are not obtained routinely to measure apoptosis directly, and neither spatial nor functional imaging is reliable for accurate response assessment. Thus, the treatmentnaive prostate cancer is best called ''androgen-stimulated,'' thus avoiding an assumption of androgen dependence, sensitivity, or resistance. Almost no men with advanced prostate cancer are cured by androgen deprivation therapy. Thus, the relative distribution of malignant epithelial cells among the androgen-dependent, androgen-sensitive, and androgen-independent compartments is really only of academic interest. Of more practical interest is the proper terminology for prostate cancer that returns clinically during androgen deprivation therapy. What should the tumor be called when it recurs after some degree of response to androgen deprivation therapy? ''Androgen-independent'' is an inappropriate term since it is now well established that prostate cancer, which recurs during surgical or medical androgen deprivation therapy, has tissue levels of testicular androgens that are sufficient for activation of even a normal androgen receptor (Geller et al. 1979; Mohler et al. 2004; Titus et al. 2005) . In fact, a recent publication has suggested that benign prostate tissue also contains levels of testicular androgens sufficient to activate the androgen receptor within 4 weeks after initiation of androgen deprivation therapy (Page et al. 2006) . ''Hormone refractory'' is an equally imprecise terminology since the prostate cancer dependence upon androgens far outweighs the magnitude of its dependence of any of the other steroid hormones and, furthermore, some recurrent prostate cancers will respond to secondary treatment with nonandrogenic steroid hormones.
When prostate cancer recurs after radiation therapy, it is often called ''radiationrecurrent.'' When prostate cancer recurs after radical prostatectomy, it is often deemed recurrent, which should more appropriately be termed ''radical prostatectomy-recurrent.'' Hence, a nomenclature is proposed when a patient with unsuccessfully treated, early-detected prostate cancer may eventually be described as having Gleason grade 4 + 3 = 7, radical prostatectomy-recurrent, salvage radiationrecurrent, castration-recurrent, anti-androgen-recurrent, taxotere-recurrent, and prednisone-recurrent prostate cancer. A similar nomenclature could be applied to xenografted cell lines or human tissue specimens. In contrast, when modeling prostate cancer in vitro, use of the term ''androgen-independent'' is appropriate when media has been properly charcoal-stripped by the investigator or androgen levels have been confirmed below the limit of detection using appropriate mass spectrometry techniques. More effective communication between translational scientists, clinical scientists, clinicians, and patients will be facilitated by proper description of androgen status, and response to treatment, of prostate cancer. Thus, the editors recommend a uniform nomenclature (see Table 1 ) that hopefully allows the reader to more easily grasp the excellent reviews provided by the contributors. 
